Published in Vaccine Weekly, February 6th, 2008
"We are seeing impressive pre-clinical results with the VacciMax(R) platform," said Dr. Randal Chase, president and CEO of IVT. "The comments from the Biologics and Genetic Therapies Directorate are much appreciated because they give us direction as we proceed with our clinical development in Canada," said Dr....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly